Brentuximab vedotin kills CD30-positive cells after binding CD30, internalization, and lysosomal release of MMAE, which binds the tubulin vinca domain to block polymerization and induce G2/M arrest and apoptosis. Tubulin expression alone does not confer susceptibility without CD30-mediated delivery.